Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma.

× No keyword cloud information.

15 in total

Review 1. Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology.

Authors: Emanuel Raschi; Fabrizio De Ponti
Journal: Intern Emerg Med Date: 2011-12-13 Impact factor: 3.397

Review 2. Arrhythmias and Other Electrophysiology Issues in Cancer Patients Receiving Chemotherapy or Radiation.

Authors: Federico Viganego; Robin Singh; Michael G Fradley
Journal: Curr Cardiol Rep Date: 2016-06 Impact factor: 2.931

Review 3. High-Content Assessment of Cardiac Function Using Heart-on-a-Chip Devices as Drug Screening Model.

Authors: Genevieve Conant; Benjamin Fook Lun Lai; Rick Xing Ze Lu; Anastasia Korolj; Erika Yan Wang; Milica Radisic
Journal: Stem Cell Rev Rep Date: 2017-06 Impact factor: 5.739

4. Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study.

Authors: Tim Eisen; Yaroslav Shparyk; Nicholas Macleod; Robert Jones; Gudrun Wallenstein; Graham Temple; Yasser Khder; Claudia Dallinger; Matus Studeny; Arsene-Bienvenu Loembe; Igor Bondarenko
Journal: Invest New Drugs Date: 2013-04-27 Impact factor: 3.850

5. Cardiotoxicity of the anticancer therapeutic agent bortezomib.

Authors: Dominika Nowis; Michał Maczewski; Urszula Mackiewicz; Marek Kujawa; Anna Ratajska; Mariusz R Wieckowski; Grzegorz M Wilczyński; Monika Malinowska; Jacek Bil; Pawel Salwa; Marek Bugajski; Cezary Wójcik; Maciej Siński; Piotr Abramczyk; Magdalena Winiarska; Anna Dabrowska-Iwanicka; Jerzy Duszyński; Marek Jakóbisiak; Jakub Golab
Journal: Am J Pathol Date: 2010-06 Impact factor: 4.307

Review 6. Cancer chemotherapy and cardiac arrhythmias: a review.

Authors: Juan Tamargo; Ricardo Caballero; Eva Delpón
Journal: Drug Saf Date: 2015-02 Impact factor: 5.606

Review 7. Pharmacokinetic considerations for new targeted therapies.

Authors: S D Baker; S Hu
Journal: Clin Pharmacol Ther Date: 2008-12-17 Impact factor: 6.875

Review 8. Cardiovascular Toxicity of Molecular Targeted Therapy in Cancer Patients: A Double-Edged Sword.

Authors: Kuan-Liang Liu; Jen-Shi Chen; Shin-Cheh Chen; Pao-Hsien Chu
Journal: Acta Cardiol Sin Date: 2013-07 Impact factor: 2.672

9. A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.

Authors: Anthony W Tolcher; Leonard J Appleman; Geoffrey I Shapiro; Alain C Mita; Frank Cihon; Arthur Mazzu; Pavur R Sundaresan
Journal: Cancer Chemother Pharmacol Date: 2010-06-03 Impact factor: 3.333

10. Concurrent evolution of cancer cachexia and heart failure: bilateral effects exist.

Authors: Seyyed M R Kazemi-Bajestani; Harald Becher; Konrad Fassbender; Quincy Chu; Vickie E Baracos
Journal: J Cachexia Sarcopenia Muscle Date: 2014-03-14 Impact factor: 12.910